FindTrial
Sign In

Partial hepatectomy

PROCEDURE3 trials

Sponsors

Huazhong University of Science and Technology, ECOG-ACRIN Cancer Research Group, Tongji Hospital

Conditions

Hepatocellular CarcinomaResectable Hepatocellular Carcinoma With High Risk of RecurrenceRupture LiverRupture, SpontaneousStage II Gallbladder Cancer AJCC v8Stage IIA Gallbladder Cancer AJCC v8Stage IIB Gallbladder Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8

Phase 2

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
Active, not recruitingNCT04559139
ECOG-ACRIN Cancer Research GroupStage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage II Gallbladder Cancer AJCC v8 +3
Start: 2021-02-24End: 2029-06-30Target: 186Updated: 2026-03-19
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Not yet recruitingNCT06954116
Tongji HospitalResectable Hepatocellular Carcinoma With High Risk of Recurrence
Start: 2025-08-01End: 2029-04-01Target: 26Updated: 2025-06-13

Unknown Phase

Management of Spontaneous Ruptured Hepatocellular Carcinoma
CompletedNCT03516890
Huazhong University of Science and TechnologyHepatocellular Carcinoma, Rupture Liver, Rupture, Spontaneous
Start: 2005-01-01End: 2017-12-01Updated: 2018-05-04